|
WO2021080999A1
|
|
Systems and methods for predicting biological responses
|
|
US2021118575A1
|
|
Systems and Methods for Designing Vaccines
|
|
WO2021021729A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
|
WO2020117618A1
|
|
Pertussis booster vaccine
|
|
WO2019191257A1
|
|
Methods of generating broadly protective vaccine compositions comprising hemagglutinin
|
|
CN112153981A
|
|
Method for producing broad protective vaccine compositions comprising neuraminidase
|
|
EP3749358A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
AU2019215216A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
EP3632465A1
|
|
Combined immunization against meningococcal disease and human papillomavirus
|
|
CN109890413A
|
|
Neisseria meningitidis vaccine
|
|
CN109890415A
|
|
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
CA3031799A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
SG10201913650WA
|
|
Modification of engineered influenza hemagglutinin polypeptides
|
|
CA3026096A1
|
|
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
US2018177861A1
|
|
Methods of use of influenza vaccine for prevention of pneumonia
|
|
AU2016274770A1
|
|
Methods of optimizing nucleotide sequences encoding engineered influenza proteins
|
|
AU2016270979A1
|
|
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
EP3303368A2
|
|
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
WO2016187073A1
|
|
Methods for immunizing against clostridium difficile
|
|
US2016045590A1
|
|
Alkylated influenza vaccines
|
